$27.7 Bn Leukapheresis Market, 2023 - Emerging Economies and Increasing Investments From Academic Institutes, Pharma-Biotech Companies, and Leading Players
DUBLIN, Aug 23, 2018 /PRNewswire/ --
The "Leukapheresis Market by Product, Leukopak, Application, End User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The global leukapheresis products market is projected to reach USD 27.7 million by 2023 from USD 19.4 million in 2018, at a CAGR of 7.4%
Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The global leukopaks market is projected to reach USD 445.6 million by 2023, at a CAGR of 46.4%. Factors contributing to the growth of these markets include the increasing incidence and prevalence of leukemia, growing demand for leukopaks for research applications, and increasing blood donations. The report analyzes the global leukapheresis products market by type, application, end user, and region.
On the basis of type of leukapheresis products, the leukapheresis disposables segment is estimated to account for the largest share of the leukapheresis products market in 2018. The large share of this segment can be attributed to the repeated consumption of disposables in leukapheresis procedures. The increasing applications of leukapheresis procedures for the isolation of primary cells from blood for cell therapy research applications is primarily driving the growth of this market segment during the forecast period.
Based on applications, the research applications segment is expected to account for the largest share of the global leukapheresis products market in 2018. The large share of this segment can be attributed to the growing adoption of leukapheresis products in research activities propelled by increasing research activities being undertaken for cancer, immunology, infectious diseases, drug discovery, regenerative medicine, and cell-based therapies.
By end user, the blood component providers & blood centers segment is expected to account for the largest share of the global leukapheresis products market in 2018. Growth in this market is primarily driven by the increasing number of blood donations, growing demand for leukopaks for the development of CAR-T therapy, and rising demand for leukopaks in clinical conditions like cancer.
The report also covers the global leukopaks market by type, indication, end user, and region. By type of leukopaks, the mobilized leukopaks segment is estimated to account for the largest share of the leukopaks market in 2018. The large share can be attributed to the increasing demand for low granulocyte and low hematocrit contamination, high cell viability, and an increase in CD34+ cell frequencies for the development of immunotherapies.
The academic & research institutes segment is expected to register the highest CAGR during the forecast period in the leukopaks market, by end user. The increasing industry-academic partnership for researching cell-based cancer therapies is driving the growth of leukopaks market for academic and research institutes, as leukopak constitutes the primary requirement of any type of research in cell biology and cancer immunotherapy.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Leukapheresis Products Market
4.1.1 Leukapheresis Products Market: Overview
4.1.2 Leukapheresis Products Market, By End User & Region (2017)
4.1.3 Geographic Snapshot of the Leukapheresis Products Market (2017)
4.1.4 Geographic Mix: Leukapheresis Products Market, 2018-2023 (USD Million)
4.1.5 Leukapheresis Products Market: Developing vs Developed Markets, 2018 vs 2023 (USD Million)
4.2 Leukopaks Market
4.2.1 Leukopaks Market: Overview
4.2.2 Leukopaks Market, By Type & Region (2017)
4.2.3 Geographic Snapshot of the Leukopaks Market (2017)
4.2.4 Geographic Mix: Leukopaks Market, 2018-2023 (USD Million)
4.2.5 Leukopaks Market: Developing vs Developed Markets, 2018 vs 2023 (USD Million)
5 Market Overview
5.1 Introduction
5.2 Market Dynamics: Impact Analysis
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence and Prevalence of Leukemia
5.2.1.2 Increasing Number of Blood Donations
5.2.1.3 Demand for Leukopaks in Clinical Research
5.2.2 Market Restraints
5.2.2.1 High Cost of Therapeutic Leukapheresis and Leukopaks
5.2.2.2 Stringent Donor Recruitment Criteria
5.2.2.3 Dearth of Skilled Professionals and Low Adoption of Therapeutic Leukapheresis
5.2.2.4 Complications Associated With Therapeutic Leukapheresis
5.2.3 Market Opportunities
5.2.3.1 Leukapheresis for Pediatric Patients
5.2.3.2 Emerging Economies and Increasing Investments From Academic Institutes, Pharma-Biotech Companies, and Leading Players
5.2.4 Market Challenges
5.2.4.1 High Cost of Cellular Immunotherapies
5.2.4.2 Blood Transfusion Safety in Developing Countries
6 Industry Insights
6.1 Industry Trends
6.1.1 Increasing Number of Collaborations Among Pharma and Biotech Companies
6.2 Leukopaks: Pricing Analysis
6.3 Regulatory Analysis
6.3.1 US
6.3.2 Europe
6.3.3 Japan
7 Leukapheresis Products Market, By Type
7.1 Introduction
7.2 Leukapheresis Devices
7.2.1 Apheresis Devices
7.2.2 Leukapheresis Columns & Cell Separators
7.2.3 Leukoreduction Filters
7.3 Leukapheresis Disposables
8 Leukapheresis Products Market, By Application
8.1 Introduction
8.2 Research Applications
8.3 Therapeutic Applications
9 Leukapheresis Products Market, By End User
9.1 Introduction
9.2 Blood Component Providers and Blood Centers
9.3 Academic and Research Institutes
9.4 Pharmaceutical and Biotechnology Companies
9.5 Hospitals and Transfusion Centers
10 Leukopaks Market
10.1 Introduction
10.2 Leukopaks Market, By Type
10.2.1 Mobilized Peripheral Blood Leukopaks
10.2.2 Non-Mobilized Peripheral Blood Leukopaks
10.2.3 Diseased Leukopaks
10.2.4 Isolated Pbmcs
10.3 Leukopaks Research Application Market, By Indication
10.4 Leukopaks Market, By End User
10.4.1 Introduction
10.4.2 Academic & Research Institutes
10.4.3 Pharmaceutical and Biotechnology Companies
10.4.4 Contract Research Organizations
11 Geographic Analysis
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.3 Europe
11.3.1 UK
11.3.2 Germany
11.3.3 Spain
11.3.4 RoE
11.4 Asia Pacific
11.4.1 China
11.4.2 Japan
11.4.3 Rest of Asia Pacific
11.5 Rest of the World
12 Competitive Landscape
12.1 Introduction
12.2 Product Portfolio Matrix
12.3 Market Share Analysis
12.3.1 Leukapheresis Products
12.3.2 Leukopaks
12.4 Competitive Situations and Trends
12.4.1 Product Launches and Enhancements
12.4.2 Agreements, Partnerships, and Collaborations
12.4.3 Mergers and Acquisitions
12.4.4 Expansions
13 Company Profiles
13.1 Asahi Kasei Medical Co., Ltd. (A Subsidiary of Asahi Kasei Corporation)
13.2 Fresenius Se & Co. KGaA
13.3 Haemonetics Corporation
13.4 Hemacare Corporation
13.5 Key Biologics, LLC.
13.6 Terumo BCT
13.7 ALLCells, LLC.
13.8 Stemexpress, LLC.
13.9 Stemcell Technologies, Inc.
13.10 Caltag Medsystems Limited
13.11 Zenbio, Inc.
13.12 Precision for Medicine, Inc.
13.13 PPA Research Group, Inc.
13.14 Bioivt
13.15 Macopharma SA
For more information about this report visit https://www.researchandmarkets.com/research/nqpqks/27_7_bn?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article